Intron A

Quick links to important sections

Intron A

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Intron A

Property Description
Active Ingredient Interferon Alfa-2b (INN)
Form Solution for Injection / Powder for Injection
Pharmacological Class Biologic Response Modifier / Cytokine
General Purpose Antiviral and cell growth-regulating support
Origin Recombinant protein (lab-made)

Defining Intron A: A Recombinant Biologic

Intron A is a specific brand of prescription medicine whose active ingredient is Interferon Alfa-2b (INN), placing it in the class of Biologic Response Modifiers and Immunomodulating Agents. This substance is a small, complex protein belonging to the cytokine family, which are essential signaling molecules naturally produced by the body's immune cells.

Interferon Alfa-2b is manufactured through recombinant DNA techniques, confirming its status as a synthetic, lab-produced protein derived from a modified strain of E. coli bacteria. This process yields a highly purified product that is structurally identical to the natural Interferon alpha protein found in human leukocytes. The medicine is clinically recognized for its ability to modulate the immune system, a characteristic supported by decades of pharmacological studies, distinguishing it as a significant component in certain treatment protocols.

Composition, Form, and General Purpose

The medication is a single-ingredient product supplied as a Solution for Injection or a Powder for Injection requiring reconstitution, which is delivered via injection (subcutaneous, intramuscular, or intravenous routes). This reliance on injection is a definitive feature of this class of recombinant proteins, as they would be deactivated by the digestive system if taken orally.

Its general purpose is rooted in its antiviral activity and capacity for antiproliferative effects (growth inhibition). These fundamental actions help the body to address cellular threats, offering support in situations requiring the suppression of rapidly dividing cells and enhanced resistance against viral pathogens.

Regulatory References

  1. Interferon Alfa-2b (Injection Route): MedlinePlus Drug Information
  2. Interferon: StatPearls - NCBI Bookshelf

What side effects are possible with Intron A?

Possible Side Effects and Safety Information

Official regulatory documentation structures the safety profile of Intron A (Interferon Alfa-2b) by classifying adverse reactions based on frequency and affected system.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by the incidence reported in clinical trials and post-market use:

  • Very Common (occurring in ge 10% of patients): These frequently reported effects often resemble an acute viral illness and include fatigue, pyrexia (fever), chills, headache, nausea, diarrhea, anorexia, and leukopenia (decreased white blood cells). Depression and injection site reactions are also very common.
  • Common (occurring in 1% to <10% of patients): Effects in this tier include dizziness, insomnia, alopecia (hair thinning), and changes in thyroid function such as hypothyroidism or hyperthyroidism.

Serious Adverse Reactions

Interferon Alfa-2b has the potential to cause or aggravate serious, life-threatening disorders across several systems. Regulatory labeling specifically documents serious neuropsychiatric disorders, including suicide, suicidal ideation, and psychoses. The potential for severe autoimmune disorders (such as Systemic Lupus Erythematosus) and serious ischemic events (cardiovascular or cerebrovascular) is also noted. Rare occurrences of severe pulmonary toxicities (e.g., interstitial pneumonitis) and sepsis have been reported.

Safety Patterns and Constraints

Safety data indicate that common influenza-like symptoms typically occur within 1 to 3 hours after injection but may decrease in intensity over time. Hematopoiesis depression, such as thrombocytopenia, is often observed during the first one to two months of treatment. Specific considerations are noted for pediatric patients due to the reported potential for long-term growth inhibition and the need for effective contraception for females of reproductive potential due to the risk of fetal harm.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose for Intron A (Interferon Alfa-2b) by focusing on the manifestation of severe, dose-related toxicities that affect multiple body systems. The management of overdose is generally symptomatic, as no specific antidote is documented in regulatory labeling.

Overdose presentations typically involve the extreme or persistent worsening of known adverse effects, which are considered dose-limiting toxicities. These manifestations include severe or unremitting flu-like symptoms (such as fever and fatigue), significant blood cell reductions (myelosuppression), and signs of serious hepatotoxicity (liver problems).

Mandatory Emergency Actions

The regulatory guidance mandates specific actions in case of suspected overdose or high exposure:

  • Call your healthcare provider right away if you take too much Intron A, as monitoring and dose adjustment or discontinuation may be required.
  • Seek immediate medical attention for life-threatening or severe complications. This is required for symptoms suggesting serious neuropsychiatric disorders (e.g., severe depression, psychosis), ischemic events, or severe allergic reactions (e.g., trouble breathing).

Close clinical and laboratory monitoring is officially required following severe exposure, especially concerning hematologic, hepatic, and neuropsychiatric status. Elderly patients are noted to be at increased risk of toxicity due to potential age-related organ impairment.

Therapeutic Uses of Intron A

What Intron A treats: Main uses and benefits

Intron A (interferon alfa-2b, recombinant) is commonly used to help with conditions involving episodic or fluctuating manifestations and is considered relevant in contexts involving heightened systemic burden. This medication is applied across domains where additional symptomatic support is needed, particularly when dealing with symptoms that create noticeable physiological strain.

The main therapeutic area is commonly used to help with conditions characterized by periods of heightened symptoms, including certain types of cancers and viral diseases. Specifically, it is applied in addressing types of leukemia (such as hairy cell leukemia), malignant melanoma, and Kaposi’s sarcoma (AIDS-related), as well as chronic viral conditions like hepatitis B and hepatitis C.

In these clinical scenarios, the medication may assist with maintaining functional stability in situations where symptoms become more noticeable, thereby contributing to improved comfort during periods of heightened symptoms. The medication may be part of symptomatic management in situations where patients experience significant symptomatic burden. This supportive relief supports patients during episodes of heightened discomfort.


Quick Fact: Applied in addressing Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH MedlinePlus overview of Interferon Alfa-2b

Eligibility and Restrictions for Use

The eligibility for using Intron A (Interferon Alfa-2b) is strictly governed by patient characteristics and pre-existing medical conditions, as defined in regulatory labeling.

Who Is Eligible for Use?

  • Adults are eligible for treatment across all labeled indications.
  • Pediatric Use is established for chronic hepatitis B in patients 1 year of age or older with compensated liver disease.
  • For chronic hepatitis C (in combination therapy), use is generally established in patients 3 years of age and older.

Who Must Not Use Intron A? (Contraindications)

Use is absolutely prohibited (contraindicated) for patients with the following conditions:

  • Autoimmune hepatitis or certain other severe immune system disorders.
  • Decompensated liver disease (liver function that is severely impaired).
  • Severe heart disease, uncontrolled thyroid disease, severe kidney disease, or epilepsy.
  • A history of severe psychiatric disorders, including severe depression or suicidal ideation.
  • Pregnant women and male patients whose partners are pregnant, when Intron A is used in combination with ribavirin.

Use is restricted or conditional in non-severe cases of chronic psychiatric illness, non-severe kidney impairment, and pre-existing autoimmune conditions like psoriasis, requiring close monitoring during therapy.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Intron A (Interferon Alfa-2b) by noting specific pharmacokinetic and pharmacodynamic relationships that impose restrictions on co-administration.

Contraindicated and Exposure-Altering Combinations

The co-administration of Fezolinetant is formally contraindicated due to Interferon Alfa-2b’s documented effect on hepatic enzyme metabolism. This is classified as a pharmacokinetic interaction that involves the inhibition of CYP1A2 activity. This documented interference with drug clearance specifically results in increased plasma concentrations and reduced clearance for certain co-administered substances, including Theophylline and Zidovudine. A population-specific note indicates that patients who are smokers may experience a greater risk of interaction severity when co-administered with Theophylline.

Additive Effects and Specific Restrictions

The profile notes several pharmacodynamic interactions. Co-administration with Hydroxyurea is associated with an additive toxicity that carries a risk of cutaneous vasculitic toxicities. Combining Intron A with immunosuppressive agents (such as Ponesimod and Siponimod) poses a risk of additive immunosuppressive effects. Furthermore, an increased risk of bleeding is documented when Intron A is co-administered with Anticoagulants (like Warfarin) and Antiplatelet agents. A formal population-based restriction applies to combination therapy: the use of Intron A with Ribavirin is contraindicated in patients with Creatinine clearance < 50 mL/min or those with hemoglobinopathies. No mandatory timing-based separation rules are explicitly documented.

Mechanism of Action

Intron A (Interferon alfa-2b) is a recombinant Type I Interferon that exerts its effects by binding to specific cell-surface receptors, namely the IFNAR1 and IFNAR2 subunits, which are present on most cell types. This binding initiates the dimerization of the receptor subunits, which activates receptor-associated Janus kinases, specifically JAK1 and TYK2.

The activated Janus kinases then phosphorylate the receptors, creating docking sites for Signal Transducers and Activators of Transcription (STAT) proteins, primarily STAT1 and STAT2. These STAT proteins are phosphorylated, forming the Interferon-Stimulated Gene Factor 3 (ISGF3) complex alongside IRF-9.

ISGF3 translocates to the cell nucleus, where it binds to the Interferon-Stimulated Response Element (ISRE) in the promoter regions of target genes. This binding upregulates the transcription of hundreds of Interferon-Stimulated Genes (ISGs). The resulting ISG products mediate various downstream intracellular consequences, including the regulation of cell proliferation, the modulation of antigen presentation, and the induction of specific protein synthesis that affects nucleic acid processes. These combined cellular processes lead to system-level immunomodulation and the regulation of cell cycle progression in target cell populations.

Dosage and Administration Information

Intron A is administered via injection, a necessity due to its nature as a protein that would be inactivated if taken orally. Official prescribing documents specify different routes, doses, and schedules based on the condition being addressed.

Administration Routes and Forms

Administration is generally via subcutaneous (SC) or intramuscular (IM) injection. The intravenous (IV) route is reserved for specific intensive periods, such as the initial Induction Phase of malignant melanoma therapy. The medicine is supplied as a solution for injection in vials or pens, or as a powder for injection that must be carefully reconstituted with the provided diluent (Sterile Water for Injection) before use. For SC and IM routes, patients are instructed to rotate the injection site.

Standard Dosing and Schedule

Official dosing is quantified in International Units (IU) and is often calculated based on the patient's body surface area (m^2). The frequency is most commonly three times a week (TIW), typically administered on alternating days.

Indication (Example Regimens) Dose & Route (Adult) Frequency & Duration (Adult)
Malignant Melanoma (Induction) 20 million IU/ m^2 (IV Infusion) 5 consecutive days/week for 4 weeks
Malignant Melanoma (Maintenance) 10 million IU/ m^2 (SC) 3 times per week for 48 weeks
Hairy Cell Leukemia 2 million IU/ m^2 (SC/IM) 3 times per week
Chronic Hepatitis C 3 million IU (SC/IM) 3 times per week

Procedural and Time-Based Rules

Intravenous administration must be performed as a 20-minute infusion after dilution in 0.9% sodium chloride solution. Many regimens, such as for malignant melanoma, involve distinct phases with different doses and routes, defining the overall duration of the course. Pediatric dosing for some conditions is also based on body surface area. If a dose is missed, patients are advised to take it as soon as possible and resume the regular schedule.

Recent Clinical Evidence

Research evidence / Overview of Studies for Intron A

Evidence for Use in Hairy Cell Leukemia (HCL)

The research exploring Intron A that has been studied for HCL relies on Multicenter Clinical Trials and Randomized Controlled Trials (RCTs). These studies were designed to examine outcomes related to haematological response, monitoring whether blood cell counts recorded defined levels, and tracking the time to treatment failure or relapse. Findings describe patterns where a measurable haematological response was recorded. However, the key trials were largely conducted prior to newer treatment options, meaning comparative evidence against current care protocols is limited.


Evidence for Chronic Viral Hepatitis

Studies for chronic Hepatitis C include RCTs that studied Intron A both as monotherapy and in combination with other agents. Outcomes measured included Virological Response (HCV RNA clearance) and Sustained Virological Response (SVR). A combination regimen was observed in some studies to yield different SVR measurements when compared to monotherapy. Separate trials were conducted to evaluate this medicine in children and adolescents, focusing on virological response in these younger populations.


Evidence for Malignant Melanoma (Adjuvant Therapy)

Research for malignant melanoma is based on large-scale RCTs involving high-risk patients who had undergone complete tumor removal. Studies focused on measuring Relapse-Free Survival (RFS) and Overall Survival (OS). Some trials reported a difference in the RFS period between the study group and the observation group. However, findings related to the primary endpoint of Overall Survival were observed to be mixed and inconsistent across analyzed trials and subsequent scientific reviews.


Evidence in Other Cancers and Research Limitations

Intron A has also been studied for other conditions, including Chronic Myelogenous Leukemia (CML), Follicular Lymphoma, and Multiple Myeloma, examining outcomes like Cytogenetic Response. The research base includes studies with long-term observational follow-up extending up to several years. However, certainty remains low for many long-term effects. The existing studies provide limited information for certain populations, and comparative evidence is lacking against the highly targeted therapies now common in clinical practice.

Key Studies & References

  1. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review

Frequently Asked Questions (FAQ)

Common questions about Intron A (FAQ)


Q: Are there any food restrictions while taking Intron A?

Official information generally advises that patients discuss the use of any medicine with food with their healthcare provider. However, regulatory documents do not typically specify overall food restrictions for this particular medication.


Q: Does Intron A interact with common pain relievers like Tylenol (acetaminophen)?

Regulatory guidance indicates that Interferon Alfa-2b may affect how the body processes certain substances, potentially increasing the concentration of medications like acetaminophen. Although some healthcare providers may recommend acetaminophen to help manage flu-like symptoms, this use is addressed in regulatory guidance and is subject to monitoring by a healthcare provider.


Q: Can older adults use Intron A?

Studies have not shown specific problems related to age that would limit the use of this injection in older adults. However, older patients are more likely to have existing conditions—such as severe liver, heart, or kidney problems—which are factors recognized in official documents as warranting caution and potentially requiring changes to the prescribed regimen.


Q: Does alcohol interact with Intron A?

Official regulatory and patient guidance describes that the use of alcohol is associated with an increased risk of liver injury while using this medication.


Q: How long does Intron A stay in your system?

According to the official product information, the medication's elimination half-life is approximately 2 to 3 hours following subcutaneous or intramuscular injection. The substance’s concentration in the bloodstream is usually below detectable limits within 16 hours after an injection.


Q: Do I need special training to give myself the injection?

Official regulatory and patient information indicates that a healthcare professional or nurse will teach the patient or caregiver how to give the injection correctly. Instruction is provided to ensure the medication is administered safely and properly before the first dose is administered outside of a clinical setting.


Q: Can Intron A affect liver enzyme levels?

Official information notes that transient increases in serum ALT (a liver enzyme) can occur during therapy. For this reason, liver function tests, including ALT, albumin, and bilirubin, are typically monitored regularly during treatment to assess the body’s response and any potential toxicity.


Q: Is it true that Intron A can cause changes in vision?

Yes, official documents and related class information mention that changes in vision have been observed in some patients. These visual changes may include blurred vision, loss of vision, and complications affecting the retina, such as hemorrhages.


Q: Can Intron A interact with herbal supplements?

Regulatory and patient guidance recommends that patients inform their care team about all herbal products and nutritional supplements they are taking. This is advised because the prescribed regimen of Intron A or other medications may need to be reviewed to prevent potential complications.


Q: Does Intron A affect the ability to drive or operate machinery?

Official patient guidance notes that this medicine may cause side effects like dizziness or drowsiness. Due to this potential, regulatory information typically includes precautions regarding driving or operating machinery until the patient is aware of how the medicine affects their concentration and coordination.


Q: Is there a generic version of Intron A available?

Intron A (Interferon Alfa-2b) has been voluntarily discontinued by the manufacturer in the United States. Therefore, there is currently no lower-cost generic version available in many regions where the brand name product was previously marketed.


Q: Can Intron A interact with diabetes medications?

Official patient guidance indicates that Interferon Alfa-2b may affect blood sugar levels and has been known to cause or aggravate hyperglycemia (high blood sugar) and diabetes mellitus. Official guidance emphasizes that patients with diabetes require close monitoring of their blood sugar levels, and they should report any changes to their healthcare provider.


Q: Is Intron A considered a type of chemotherapy?

Intron A is classified in regulatory documents as an Antineoplastic Interferon and a Biologic Response Modifier. While it is used in the treatment of some cancers, it is not categorized as a traditional cytotoxic chemotherapy agent.


Q: Can Intron A be used long-term?

Studies and regulatory documents reflect that treatment regimens for some conditions, such as malignant melanoma, involve extended periods. This includes a 48-week maintenance phase, and the evidence base for the medication includes studies with long-term patient follow-up.


Q: Is Intron A safe to use during pregnancy (as described in regulatory sources)?

Official regulatory documents indicate a potential risk of fetal harm and require that women of reproductive potential use effective contraception during treatment. When the medicine is used in combination with ribavirin, it is strictly prohibited for pregnant women and for male patients whose partners are pregnant.


Q: Is Intron A the same as interferon alpha?

Intron A is the brand name for the active ingredient, Interferon Alfa-2b, recombinant. This drug is a synthetic version of the naturally occurring Interferon alpha protein that the body’s immune system produces.


Q: Why is fatigue a common side effect of Intron A?

Interferon Alfa-2b is an immunomodulator that works by regulating the immune system. This action can lead to increased levels of proteins in the body that can cause symptoms resembling a viral illness, such as fever and fatigue, which is reported as a very common side effect.


Q: Does Intron A interact with birth control pills?

Official safety guidance requires the use of effective contraception for females of reproductive potential due to the risk of fetal harm. However, product information does not explicitly state an interaction that would reduce the effectiveness of oral contraceptive pills themselves.


Q: Do you always have to inject Intron A in the stomach or can it be other places?

For subcutaneous injection, the medication can be administered in several areas, not just the stomach. Official instructions permit injection into the stomach area (avoiding the navel and waistline), upper arms, or thighs. Patients are always instructed to rotate the injection site.


Q: Can Intron A cause weight changes?

Official sources have reported weight loss as a common side effect in clinical trials. Anorexia (loss of appetite) is also listed as a very common adverse reaction, which can lead to a decrease in weight.


Q: What kind of monitoring tests are usually done while on Intron A?

Regulatory guidance requires regular testing to monitor safety and response. This typically includes blood tests like a CBC (Complete Blood Count), platelet counts, and liver function tests (such as serum ALT), which are assessed both before and throughout the course of therapy.


Q: What is the chance of getting an infection while on Intron A?

Official safety information notes that Interferon Alfa-2b can cause or aggravate infectious disorders. A very common side effect is leukopenia (a decrease in white blood cells), which can increase the risk of infection. Rare, serious outcomes like sepsis have also been reported.


Q: Can men use Intron A if they are planning to father a child?

Male patients are required to avoid using the medicine when their partners are pregnant if the medicine is taken in combination with ribavirin. Men are also generally advised to use effective contraception due to the documented risk of fetal harm.

How should Intron A be stored and disposed of?

Official Storage and Disposal Requirements for Intron A

Intron A (Interferon Alfa-2b) must be stored under specific, controlled conditions as defined by regulatory labeling to maintain effectiveness.

Storage Conditions

The product must be stored in a refrigerator between 2 C and 8 C (36 F and 46 F). Do not freeze Intron A, and do not use the solution if it has changed color or contains particles. The powder for injection may be stored at room temperature (up to 25 C) for up to four weeks before reconstitution.

Stability and Handling

After the first use or reconstitution, the product has a limited shelf-life; for example, most multi-dose pens or vials must be used within four weeks when stored in the refrigerator. After reconstitution with Bacteriostatic Water, the product is stable for up to 30 days when refrigerated. Keep all forms of Intron A out of the reach of children.

Disposal

Used syringes and needles must be immediately placed in a puncture-resistant sharps container. Do not dispose of unused or expired medicine by pouring it down a drain or placing it in household trash. Consult a pharmacist or healthcare provider for instructions on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Intron A found in:

A-Z Index: